ANVS

Annovis Bio, Inc.

Price Chart

No historical data available

Latest Quote

$1.72

-0.09 (-4.97%)

Current Price

Previous Close	$1.81
Open	$1.78
Day High	$1.83
Day Low	$1.71
Volume	498,121

Fetched: 2026-08-29T19:58:42

Stock Information

Shares Outstanding	42.61M
Cash Equivalents	$18.73M
Net Income	$-49.52M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$73.28M
EPS (TTM)	$-1.75
Exchange	NYQ

🌐 Visit Website

Recent Price History

No history data available. Data will be fetched automatically.

About Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

📰 Latest News

No news articles available at the moment. Check back later for updates on ANVS.

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$29,695,258	$26,694,928	$45,035,011	$25,511,279
Other Income Expense	$142,000	$3,625,893	$-11,837,200	-
Net Non Operating Interest Income Expense	$699,061	$-1,521,340	$667,898	$182,712
Operating Expense	$29,695,258	$26,694,928	$45,035,011	$25,511,279
General And Administrative Expense	$4,479,651	$6,699,481	$6,244,408	$8,995,736
Total Other Finance Cost	-	$1,853,189	-	-
Other Operating Expenses	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-28,854,197	$-24,590,375	$-56,204,313	$-25,328,567
Net Interest Income	$699,061	$-1,521,340	$667,898	$182,712
Interest Income	$699,061	$331,849	$667,898	$182,712
Normalized Income	$-28,996,197	$-28,216,268	$-44,367,113	$-25,328,567
Net Income From Continuing And Discontinued Operation	$-28,854,197	$-24,590,375	$-56,204,313	$-25,328,567
Total Operating Income As Reported	$-29,695,258	$-26,694,928	$-45,035,011	$-25,511,279
Average Dilution Earnings	$0	$-3,625,893	$0	-
Net Income Common Stockholders	$-28,854,197	$-24,590,375	$-56,204,313	$-25,328,567
Net Income	$-28,854,197	$-24,590,375	$-56,204,313	$-25,328,567
Net Income Including Noncontrolling Interests	$-28,854,197	$-24,590,375	$-56,204,313	$-25,328,567
Net Income Continuous Operations	$-28,854,197	$-24,590,375	$-56,204,313	$-25,328,567
Pretax Income	$-28,854,197	$-24,590,375	$-56,204,313	$-25,328,567
Interest Income Non Operating	$699,061	$331,849	$667,898	$182,712
Operating Income	$-29,695,258	$-26,694,928	$-45,035,011	$-25,511,279
Per Share
Diluted EPS	$-1.40	$-2.31	$-6.23	$-3.10
Basic EPS	$-1.40	$-2.02	$-6.23	$-3.10
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-29,837,258	$-30,320,821	$-33,197,811	$-25,511,279
Total Unusual Items	$142,000	$3,625,893	$-11,837,200	-
Total Unusual Items Excluding Goodwill	$142,000	$3,625,893	$-11,837,200	-
EBITDA (Bullshit earnings)	$-29,695,258	$-26,694,928	$-45,035,011	$-25,511,279
EBIT	$-29,695,258	$-26,694,928	$-45,035,011	$-25,511,279
Diluted Average Shares	$20,551,997	$12,235,444	$9,023,138	$8,162,326
Basic Average Shares	$20,551,997	$12,182,475	$9,023,138	$8,162,326
Diluted NI Availto Com Stockholders	$-28,854,197	$-28,216,268	$-56,204,313	$-25,328,567
Gain On Sale Of Security	$142,000	$3,625,893	$-11,837,200	-
Research And Development	$25,215,607	$19,995,447	$38,790,603	$16,515,543
Selling General And Administration	$4,479,651	$6,699,481	$6,244,408	$8,995,736
Other Gand A	$4,479,651	$6,699,481	$6,244,408	$8,995,736
Provision For Doubtful Accounts	-	-	$0	$0

Fetched: 2026-08-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$16,851,250	$9,307,646	$-7,750,846	$28,323,530
Total Assets	$21,081,625	$13,925,633	$10,208,264	$36,022,069
Total Non Current Assets	$0	$0	$0	$0
Current Assets	$21,081,625	$13,925,633	$10,208,264	$36,022,069
Prepaid Assets	$1,549,287	$3,373,717	$4,453,544	$7,644,376
Cash Cash Equivalents And Short Term Investments	$19,532,338	$10,551,916	$5,754,720	$28,377,693
Cash And Cash Equivalents	$19,532,338	$10,551,916	$5,754,720	$28,377,693
Liabilities
Total Liabilities Net Minority Interest	$4,230,375	$4,617,987	$17,959,110	$7,698,539
Total Non Current Liabilities Net Minority Interest	$595,000	$737,000	$13,680,000	$0
Derivative Product Liabilities	$595,000	$737,000	$13,680,000	$0
Current Liabilities	$3,635,375	$3,880,987	$4,279,110	$7,698,539
Payables And Accrued Expenses	$3,635,375	$3,880,987	$4,279,110	$7,698,539
Payables	$2,590,516	$2,305,974	$1,292,837	$3,961,254
Accounts Payable	$2,590,516	$2,305,974	$1,292,837	$3,961,254
Equity
Common Stock Equity	$16,851,250	$9,307,646	$-7,750,846	$28,323,530
Total Equity Gross Minority Interest	$16,851,250	$9,307,646	$-7,750,846	$28,323,530
Stockholders Equity	$16,851,250	$9,307,646	$-7,750,846	$28,323,530
Retained Earnings	$-163,703,659	$-134,849,462	$-110,259,087	$-54,054,774
Other
Ordinary Shares Number	$27,199,139	$14,141,521	$10,519,933	$8,163,923
Share Issued	$27,199,139	$14,141,521	$10,519,933	$8,163,923
Tangible Book Value	$16,851,250	$9,307,646	$-7,750,846	$28,323,530
Invested Capital	$16,851,250	$9,307,646	$-7,750,846	$28,323,530
Working Capital	$17,446,250	$10,044,646	$5,929,154	$28,323,530
Total Capitalization	$16,851,250	$9,307,646	$-7,750,846	$28,323,530
Additional Paid In Capital	$180,552,190	$144,155,694	$102,507,189	$82,377,488
Capital Stock	$2,719	$1,414	$1,052	$816
Common Stock	$2,719	$1,414	$1,052	$816
Preferred Stock	$0	$0	$0	$0
Current Accrued Expenses	$1,044,859	$1,575,013	$2,986,273	$3,737,285
Treasury Shares Number	-	-	$0	-

Fetched: 2026-08-22

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-25,619,703	$-21,894,604	$-39,967,304	$-17,312,934
Operating Activities
Operating Cash Flow	$-25,619,703	$-21,894,604	$-39,967,304	$-17,312,934
Cash Flow From Continuing Operating Activities	$-25,619,703	$-21,894,604	$-39,967,304	$-17,312,934
Operating Gains Losses	$-142,000	$-3,625,893	$11,837,200	-
Financing Activities
Issuance Of Capital Stock	$34,598,126	$18,666,797	$16,885,946	$0
Financing Cash Flow	$34,600,125	$26,691,800	$17,344,331	$4,613
Cash Flow From Continuing Financing Activities	$34,600,125	$26,691,800	$17,344,331	$4,613
Net Common Stock Issuance	$34,598,126	$18,666,797	$16,885,946	$0
Common Stock Issuance	$34,598,126	$18,666,797	$16,885,946	$0
Other
End Cash Position	$19,532,338	$10,551,916	$5,754,720	$28,377,693
Beginning Cash Position	$10,551,916	$5,754,720	$28,377,693	$45,686,014
Changes In Cash	$8,980,422	$4,797,196	$-22,622,973	$-17,308,321
Proceeds From Stock Option Exercised	$1,999	$8,025,003	$458,385	$4,613
Change In Working Capital	$1,578,818	$681,705	$-228,597	$-1,136,887
Change In Payables And Accrued Expense	$-245,612	$-398,122	$-3,419,429	$6,192,025
Change In Accrued Expense	$-530,154	$-1,411,260	$-751,012	$2,918,845
Change In Payable	$284,542	$1,013,138	$-2,668,417	$3,273,180
Change In Account Payable	$284,542	$1,013,138	$-2,668,417	$3,273,180
Change In Prepaid Assets	$1,824,430	$1,079,827	$3,190,832	$-7,328,912
Stock Based Compensation	$1,797,676	$3,836,770	$4,628,406	$9,152,520
Gain Loss On Investment Securities	$-142,000	$-3,625,893	$11,837,200	-
Net Income From Continuing Operations	$-28,854,197	$-24,590,375	$-56,204,313	$-25,328,567
Other Non Cash Items	-	$1,803,189	-	-
Change In Receivables	-	-	-	-

Fetched: 2026-08-22